Amgen "market perform"

29.08.07 - Rodman & Renshaw

NEW YORK, August 29 (newratings.com) - Analyst Michael G King Jr of Rodman & Renshaw reiterates his "market perform" rating on Amgen Inc (AMGN).

In a research note published yesterday, the analyst mentions that a federal court has ruled that one of the company?s erythropoietin (EPO) patent has been infringed by Roche. Amgen?s further arguments on additional patent infringements by Roche will be heard on September 4, the analyst says. The favourable ruling gives the company an edge over Roche in further trials, Rodman & Renshaw adds.